International Journal of Hematology

DOI: 10.1007/s12185-012-1199-2 Pages: 535-543

Advances in the treatment of Hodgkin lymphoma

1. University Hospital Cologne, First Department of Internal Medicine

2. German Hodgkin Study Group (GHSG)

Correspondence to:
Andreas Engert
Tel: +49-221-4785933
Fax: +49-221-4783778



In the past decades, Hodgkin lymphoma (HL) has turned from an incurable disease to one with the most favorable prognosis among adult malignancies. This is due to the introduction of effective multi-agent chemotherapy and the optimization of radiation techniques. At present, 80–90 % of patients achieve long-term remission when receiving appropriate first-line treatment. Even in case of relapse, up to 50 % can be successfully salvaged with high-dose chemotherapy and autologous stem cell transplantation. Thus, current studies do not necessarily aim at increasing treatment efficacy but rather focus on a possible reduction of acute and late toxicity by decreasing treatment intensity if possible. One promising strategy to spare therapy in good-risk patients is early response-adapted treatment stratification according to the result of interim positron emission tomography. The evaluation of novel drugs and the optimization of treatment for elderly HL patients and those with nodular lymphocyte-predominant HL are further aspects that are currently being addressed in ongoing trials. This review will give an overview on more recent clinical trials and discuss possible future strategies for the treatment of HL.

This article is freely available, click here to access the full text/PDF

Share the Knowledge